<DOC>
	<DOCNO>NCT01006603</DOCNO>
	<brief_summary>This study evaluate efficacy tolerability saxagliptin compare glimepiride elderly patient type 2 diabetes mellitus inadequate glycaemic control metformin monotherapy .</brief_summary>
	<brief_title>Saxagliptin Compared Glimepiride Elderly Type 2 Diabetes Patients , With Inadequate Glycemic Control Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Established clinical diagnosis type 2 diabetes . Treatment stable metformin monotherapy , least 8 week prior Visit 1 HbA1c ≥7.0 % ≤9.0 % Type 1 diabetes , history diabetic ketoacidosis hyperosmolar nonketonic coma . Current use injectable oral antihyperglycemic agent exclude metformin . Renal impairment define creatinine clearance &lt; 60 mL/min Individuals , opinion investigator , participation study may pose significant risk patient could render patient unable successfully complete study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>elderly patient</keyword>
	<keyword>saxagliptin</keyword>
	<keyword>randomise</keyword>
	<keyword>double-blind</keyword>
</DOC>